← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Precision BioSciences, Inc. (DTIL) 10-Year Financial Performance & Capital Metrics

DTIL •
HealthcareBiotechnologyRNA and Genome Editing Developers
AboutPrecision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.Show more
  • Revenue $69M +41.0%
  • EBITDA -$22M +39.2%
  • Net Income $7M +111.7%
  • EPS (Diluted) 1.04 +106.5%
  • Gross Margin 100%
  • EBITDA Margin -31.42% +56.8%
  • Operating Margin -38.08% +57.6%
  • Net Margin 10.43% +108.3%
  • ROE 19.05% +112.3%
  • ROIC -
  • Debt/Equity 0.53 -67.9%
  • Interest Coverage -14.68 +25.1%
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Strong 5Y sales CAGR of 25.3%
  • ✓Trading at only 0.5x book value

✗Weaknesses

  • ✗Negative free cash flow
  • ✗Shares diluted 79.2% in last year
  • ✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y25.3%
3Y-15.91%
TTM-99.07%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM-1069.52%

EPS CAGR

10Y-
5Y-
3Y-
TTM-2004.83%

ROCE

10Y Avg-36.38%
5Y Avg-37.12%
3Y Avg-29.39%
Latest-22.63%

Peer Comparison

RNA and Genome Editing Developers
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
ALNYAlnylam Pharmaceuticals, Inc.44.07B332.92142.8865.19%8.45%39.76%1.06%3.76
SLXNWSilexion Therapeutics Ltd.63.6M0.030.00-132.54%
EDITEditas Medicine, Inc.205.18M2.20-0.76-58.64%-430.84%-14.85%0.26
SGMOSangamo Therapeutics, Inc.92.01M0.43-0.88-67.2%-331.28%-17.44%1.34
CAMPCAMP4 Therapeutics Corporation210.49M4.49-1.6986.29%-14.04%-133.54%0.14
SLNSilence Therapeutics plc256.95M5.44-1.7170.47%-252.16%-84.61%0.00
PEPGPepGen Inc.202.89M6.22-2.18-57.35%0.16
ARCTArcturus Therapeutics Holdings Inc.224.14M8.23-2.74-12.27%-72.48%-29.71%0.12

Compare DTIL vs Peers

Analyze head-to-head performance against top industry competitors across valuation, growth, and profitability metrics.

vs ALNY

Compare head-to-head with Alnylam Pharmaceuticals, Inc.

vs IONS

Compare head-to-head with Ionis Pharmaceuticals, Inc.

Compare Top 5

vs ALNY, IONS, ARWR, CRSP

Profit & Loss

Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+7.01M6.48M10.88M22.24M24.29M115.53M25.1M48.73M68.7M
Revenue Growth %--7.57%67.84%104.34%9.21%375.72%-78.28%94.15%40.98%
Cost of Goods Sold+000000000
COGS % of Revenue---------
Gross Profit+7.01M6.48M10.88M22.24M24.29M115.53M25.1M48.73M68.7M
Gross Margin %100%100%100%100%100%100%100%100%100%
Gross Profit Growth %--7.57%67.84%104.34%9.21%375.72%-78.28%94.15%40.98%
Operating Expenses+15.2M28.34M58.8M109.44M134.11M154.91M87.41M92.46M94.86M
OpEx % of Revenue216.72%437.08%540.25%492.14%552.25%134.08%348.26%189.76%138.08%
Selling, General & Admin6.1M8.02M13.67M27.03M36.05M39.67M41.28M39.09M35.3M
SG&A % of Revenue86.97%123.63%125.64%121.53%148.45%34.34%164.49%80.22%51.38%
Research & Development9.1M20.32M45.12M82.42M98.06M115.24M46.12M53.38M59.56M
R&D % of Revenue129.75%313.45%414.61%370.61%403.79%99.75%183.77%109.54%86.7%
Other Operating Expenses000000000
Operating Income+-8.83M-21.97M-47.91M-87.2M-109.83M-39.38M-62.31M-43.74M-26.16M
Operating Margin %-125.84%-338.9%-440.25%-392.14%-452.25%-34.08%-248.26%-89.76%-38.08%
Operating Income Growth %--148.91%-118.04%-82.01%-25.94%64.15%-58.24%29.81%40.18%
EBITDA+-8.19M-20.54M-45.56M-81.89M-100.02M-29.18M-53.3M-35.48M-21.59M
EBITDA Margin %-116.72%-316.76%-418.62%-368.23%-411.84%-25.26%-212.38%-72.82%-31.42%
EBITDA Growth %--150.84%-121.81%-79.74%-22.14%70.83%-82.68%33.44%39.16%
D&A (Non-Cash Add-back)640K1.44M2.35M5.32M9.81M10.2M9M8.26M4.58M
EBIT-8.26M-21.86M-46.04M-92.69M-109.01M-30.47M-71.8M-40.3M8.95M
Net Interest Income+0872K1.88M4.08M822K76K2.36M5.46M4.98M
Interest Income570K872K1.88M4.27M822K208K3.47M7.69M6.76M
Interest Expense000182K0132K1.11M2.23M1.78M
Other Income/Expense572K872K1.88M-5.67M822K8.77M-10.6M1.21M33.33M
Pretax Income+-8.26M-21.1M-46.04M-92.88M-109.01M-30.6M-72.91M-42.53M7.17M
Pretax Margin %-117.69%-325.45%-423.02%-417.65%-448.86%-26.49%-290.5%-87.28%10.43%
Income Tax+-5K00000000
Effective Tax Rate %99.94%100%100%100%100%100%153.12%144.19%100%
Net Income+-8.25M-21.1M-46.04M-92.88M-109.01M-30.6M-111.64M-61.32M7.17M
Net Margin %-117.62%-325.45%-423.02%-417.65%-448.86%-26.49%-444.8%-125.84%10.43%
Net Income Growth %--155.75%-118.16%-101.74%-17.37%71.93%-264.8%45.07%111.69%
Net Income (Continuing)-8.25M-21.1M-46.04M-92.88M-109.01M-30.6M-72.91M-42.53M7.17M
Discontinued Operations000000-38.73M-18.79M0
Minority Interest000000000
EPS (Diluted)+-0.49-18.81-28.17-59.50-62.85-15.60-38.10-15.961.04
EPS Growth %--3738.78%-49.76%-111.22%-5.63%75.18%-144.23%58.11%106.52%
EPS (Basic)-0.49-18.81-28.17-59.50-62.85-15.60-38.10-15.961.05
Diluted Shares Outstanding16.74M1.12M1.63M1.4M1.73M1.96M2.93M3.84M6.88M
Basic Shares Outstanding16.74M1.12M1.63M1.4M1.73M1.96M2.93M3.84M6.83M
Dividend Payout Ratio---------

Balance Sheet

Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+94.4M64.33M115.67M193.67M105.56M161.75M199.1M136.36M94.99M
Cash & Short-Term Investments93.42M62.8M103.19M180.89M89.8M143.66M189.58M116.68M86.31M
Cash Only93.42M62.8M103.19M180.89M89.8M143.66M189.58M116.68M85.9M
Short-Term Investments00000000413K
Accounts Receivable386K22K523K965K10M488K720K12.8M1.7M
Days Sales Outstanding20.081.2417.5415.84150.31.5410.4795.879.02
Inventory000000000
Days Inventory Outstanding---------
Other Current Assets070K3.05M2.32M4K169K2.78M906K538K
Total Non-Current Assets+4.01M8.35M22.93M41.56M44.59M49.74M39.06M23.42M41.4M
Property, Plant & Equipment3.54M8.14M21.15M39.57M41.5M29.33M13.78M14.6M10.18M
Fixed Asset Turnover1.98x0.80x0.51x0.56x0.59x3.94x1.82x3.34x6.75x
Goodwill000000000
Intangible Assets090K1.47M1.43M1.37M2.05M731K400K622K
Long-Term Investments000006.84M4.75M3.21M3.21M
Other Non-Current Assets468K124K312K558K1.72M11.52M19.81M5.21M27.39M
Total Assets+98.41M72.68M138.6M235.23M150.16M211.5M238.17M159.78M136.39M
Asset Turnover0.07x0.09x0.08x0.09x0.16x0.55x0.11x0.30x0.50x
Asset Growth %--26.15%90.69%69.72%-36.17%40.85%12.61%-32.91%-14.64%
Total Current Liabilities+8.34M9.2M14.07M26.93M42.83M35.98M59.66M49.99M14.98M
Accounts Payable1.29M1.81M2.22M2.04M792K1.14M653K2.97M1.31M
Days Payables Outstanding---------
Short-Term Debt000000022.41M0
Deferred Revenue (Current)6.21M5.82M8.44M16.49M30.24M21.24M46.19M12.04M2.96M
Other Current Liabilities845K590K2.46M6.01M6.6M7.74M9.31M9.88M7.38M
Current Ratio11.32x6.99x8.22x7.19x2.46x4.50x3.34x2.73x6.34x
Quick Ratio11.32x6.99x8.22x7.19x2.46x4.50x3.34x2.73x6.34x
Cash Conversion Cycle---------
Total Non-Current Liabilities+94.82M89.85M84.56M69.99M62.9M84.35M118.07M90.93M65.02M
Long-Term Debt000002.48M22.22M022.32M
Capital Lease Obligations00008.59M4.81M1.06M7.72M6.4M
Deferred Tax Liabilities000000000
Other Non-Current Liabilities433K1.25M1.76M4.09M392K44K1.92M128K2.99M
Total Liabilities103.16M99.05M98.64M96.92M105.73M120.33M177.74M140.92M80M
Total Debt+000010.52M9.11M24.96M31.27M30.05M
Net Debt-93.42M-62.8M-103.19M-180.89M-79.28M-134.55M-164.62M-85.41M-55.85M
Debt / Equity----0.24x0.10x0.41x1.66x0.53x
Debt / EBITDA---------
Net Debt / EBITDA---------
Interest Coverage----479.14x--298.30x-56.08x-19.61x-14.68x
Total Equity+-4.75M-26.37M39.96M138.31M44.42M91.17M60.43M18.86M56.39M
Equity Growth %--455.25%251.54%246.13%-67.88%105.22%-33.71%-68.79%198.99%
Book Value per Share-0.28-23.5124.4598.8025.6146.6020.634.918.19
Total Shareholders' Equity-4.75M-26.37M39.96M138.31M44.42M91.17M60.43M18.86M56.39M
Common Stock0000001K1K1K
Retained Earnings-18.01M-39.11M-85.19M-177.07M-286.07M-316.68M-428.31M-489.63M-482.46M
Treasury Stock0-952K-952K-952K-952K-952K-952K-952K-952K
Accumulated OCI0-3.19M-5.48M000000
Minority Interest000000000

Cash Flow

Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+92.27M-24.17M-51.72M-73.64M-87.39M-10.85M-45.75M-84.11M-58.45M
Operating CF Margin %1315.38%-372.75%-475.26%-331.13%-359.84%-9.39%-182.3%-172.62%-85.08%
Operating CF Growth %--126.19%-114.01%-42.37%-18.67%87.58%-321.57%-83.84%30.52%
Net Income-8.25M-21.1M-46.04M-92.88M-109.01M-30.6M-111.64M-61.32M7.17M
Depreciation & Amortization640K1.44M2.35M5.32M9.81M10.2M9M8.26M4.58M
Stock-Based Compensation0419K2.45M013.79M16.51M19.2M14.04M12.6M
Deferred Taxes000000000
Other Non-Cash Items1.37M174K14K16.28M35K-26.55M13.57M-3.6M-28.79M
Working Capital Changes99.72M-5.09M-10.51M-2.36M-2.01M19.58M24.11M-41.49M-54M
Change in Receivables00-523K-441K-9.04M9.51M-232K-181K10.42M
Change in Inventory00-5.95M000000
Change in Payables82K864K-673K667K-1.46M867K153K1.51M-2.1M
Cash from Investing+-2.08M-5.51M-15.66M-24.67M-5.03M-5.8M-3.32M5.83M-215K
Capital Expenditures-2.08M-5.57M-15.68M-24.67M-5.03M-5.05M-3.32M-2.28M-250K
CapEx % of Revenue29.58%85.83%144.06%110.92%20.72%4.37%13.22%4.67%0.36%
Acquisitions050K15K00008M60K
Investments---------
Other Investing050K15K00-750K0107K-25K
Cash from Financing+-12.38M-937K107.78M176M1.33M70.52M94.98M5.39M50.45M
Debt Issued (Net)00039.55M02.47M19.8M0-37K
Equity Issued (Net)49K-952K1000K1000K01000K1000K1000K1000K
Dividends Paid000000000
Share Repurchases0-952K0000000
Other Financing-12.43M15K-1.97M01.33M7.57M835K401K249K
Net Change in Cash77.82M-30.62M40.39M77.69M-91.09M53.87M45.91M-72.9M-8.21M
Free Cash Flow+90.2M-29.73M-67.4M-98.3M-92.42M-16.66M-49.07M-86.39M-58.7M
FCF Margin %1285.8%-458.57%-619.32%-442.05%-380.55%-14.42%-195.52%-177.3%-85.44%
FCF Growth %--132.96%-126.68%-45.85%5.99%81.98%-194.62%-76.05%32.06%
FCF per Share5.39-26.51-41.24-70.22-53.28-8.51-16.75-22.49-8.53
FCF Conversion (FCF/Net Income)-11.18x1.15x1.12x0.79x0.80x0.35x0.41x1.37x-8.15x
Interest Paid0000068K824K00
Taxes Paid000000000

Key Ratios

Metric201620172018201920202021202220232024
Return on Equity (ROE)---677.46%-104.2%-119.3%-45.14%-147.28%-154.66%19.05%
Gross Margin100%100%100%100%100%100%100%100%100%
Net Margin-117.62%-325.45%-423.02%-417.65%-448.86%-26.49%-444.8%-125.84%10.43%
Debt / Equity----0.24x0.10x0.41x1.66x0.53x
Interest Coverage----479.14x--298.30x-56.08x-19.61x-14.68x
FCF Conversion-11.18x1.15x1.12x0.79x0.80x0.35x0.41x1.37x-8.15x
Revenue Growth--7.57%67.84%104.34%9.21%375.72%-78.28%94.15%40.98%

Deep Dive Analysis

Explore detailed financial history, valuation models, and returns analysis

Valuation Overview

DCF models, peer multiples & analyst estimates

Total Return Calculator

Historical returns with dividends reinvested

Dividend History

Yield, growth, payout safety & DRIP calculator

Earnings History

EPS trends, net income & profitability analysis

Price History

Long-term charts & historical price data

Revenue History

Sales growth patterns & revenue breakdown

Financial Ratios

30 years of valuation, profitability & efficiency metrics

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.